SEC Form 4 · accession 0001104659-17-030597
ALPINE IMMUNE SCIENCES, INC. · ALPN
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Robert E Conway
Director
Period of report
May 4, 2017
Accepted (ET)
May 8, 2017 · 2:00 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001626199
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | May 4, 2017 | P | 10,000 | $2.26 | A | 20,000 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1The price recorded in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $2.247 to $2.288, inclusive. The reporting person undertakes to provide Nivalis Therapeutics, Inc., any security holder of Nivalis Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this Form 4.